Fujifilm is currently accelerating business growth of Life Sciences field and continues to aggressively invest in both capital and technology in its bio CDMO business, said Teiichi Goto, president and chief executive officer, representative director, FUJIFILM Corporation. This partnership and acquisition was first announced in January 2022. As part of a long-term manufacturing and services agreement, FUJIFILM Diosynth Biotechnologies will support the production of Ataras promising clinical and commercial-stage allogeneic cell therapies at the site, including tabelecleucel (tab-cel), currently in phase 3 clinical development and under review to support registration in Europe, for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+PTLD). Atara Biotherapeutics Announces the Completion of the Acquisition of Its Cell Therapy Manufacturing Facility & Commencement of April 4, 2022, 8:01 PM UTC Share this article Atara has retained a talented Technical Operations team who will continue to manage external manufacturing partnerships, manufacturing process science & development, quality assurance, supply chain, and logistics. Atara Biotherapeutics Strengthens Board; Senior Management Team FUJIFILM Diosynth Biotechnologies will also expand use of the Thousand Oaks site to manufacture a broader portfolio of cell therapies by leveraging the experience and expertise of the manufacturing and quality staff who transitioned to FUJIFILM Diosynth Biotechnologies. Atara Biotherapeutics Announces $31 Million Royalty Interest Financing In connection with this announcement, Atara will host a webcast and conference call today at 4pm PST / 7pm EST. FUJIFILM Diosynth Biotechnologies will retain 134 employees in manufacturing and quality positions at the site. For more information, please visit: https://www.fujifilmholdings.com. Except as otherwise required by law, Atara disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise. With our lead program in Phase 3 clinical development and currently under review to support registration in Europe, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. TOKYO, April 4, 2022 FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced that it has completed the acquisition of a dedicated cell therapy manufacturing facility from Atara Biotherapeutics, Inc. (Nasdaq: ATRA) for USD 100 million. About FUJIFILM Corporation Under the terms of the deal, Atara will receive USD 100 million at closing and Fujifilm plans to offer positions to approximately 140 current highly skilled manufacturing and quality staff at the site. We are incredibly proud of our world-class ATOM staff and facility and believe that this strategic partnership will meet our long-term manufacturing needs. Multicancer Screening Market - A Global and Regional Analysis: Focus on This acquisition is expected to be completed in April 2022, subject to expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions. Following completion of the transaction, FDB, a leading contract development and manufacturing organization (CDMO) in advanced therapies, will provide Atara with access to the flexible capacity and specific capability needed to manufacture clinical and commercial-stage allogeneic cell therapies for its maturing and promising pipeline, including tabelecleucel (tab-cel), under regulatory review in Europe for EBV+ PTLD, ATA188 for multiple sclerosis, and allogeneic CAR T therapies, ATA3271 and ATA3219. About Atara Biotherapeutics, Inc. Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. This information is preliminary, has not been audited, and is subject to change upon the audit of the companys financial statements for the year ended December 31, 2021. Atara Biotherapeutics Enters Strategic Manufacturing Partnership with FUJIFILM Diosynth Biotechnologies has over thirty years of experience in the development and manufacturing of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules, viral products and medical countermeasures expressed in a wide array of microbial, mammalian, and host/virus systems. Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. Atara has retained a talented Technical Operations team who will continue to manage external manufacturing partnerships, manufacturing process science & development, quality assurance, supply chain, and logistics. FUJIFILM Diosynth Biotechnologies will retain 134 employees in manufacturing and quality positions at the site. FUJIFILM Holdings America Corporation. With the addition of the dedicated site in California, Fujifilm continues to build for the future to meet the growing need of advanced therapies globally., We are excited to welcome 134 new team members to the FUJIFILM Diosynth Biotechnologies family today with the acquisition of the dedicated cell therapy manufacturing facility. United States of America SOUTH SAN FRANCISCO, Calif.-- (BUSINESS WIRE)-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM QIMR Berghofer In 2015, we obtained an exclusive license to develop and commercialize immunotherapies utilizing technology developed by Dr. Rajiv Khanna. HCRx has $6.3 billion in cumulative capital commitments with offices in Stamford (CT), San Francisco, Boston, and London. Mitsubishi Corporation is a 20% shareholder of FUJIFILM Diosynth Biotechnologies UK, Research Triangle Park, North Carolina, Watertown, Massachusetts and College Station, Texas sites. +1 919 337 4400, Belasis Avenue Evercore Group LLC is acting as strategic advisor to Atara and Gibson Dunn & Crutcher LLP is acting as its legal counsel. We will now confidently further focus our capital resources on development and commercialization of our pipeline of first-in-kind therapeutics for severe diseases.. Atara Biotherapeutics, Inc.: , , Eric Hyllengren Morrisville, NC 27560 Fujifilm Expands its Advanced Therapies CDMO Business with the Acquisition of a Dedicated Cell Therapy Manufacturing Facility from Atara Biotherapeutics, Inc. TOKYO - FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced that it has entered into an agreement to acquire a cell therapy manufacturing . Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. Strength, Multiple Fujifilm Expands its Advanced Therapies CDMO Business with the Acquisition of a Dedicated Cell Therapy Manufacturing Facility from Atara Biotherapeutics, Inc. Actively contributed and participated in the acquisition of Atara Biotherapeutics. FUJIFILM Diosynth Biotechnologies California, Inc. entered into an asset purchase agreement to acquire T-Cell Operations and Manufacturing Facility in Thousand Oaks, California from Atara Biotherapeutics, Inc. (NasdaqGS:ATRA) for $100 million on January 26, 2022. Efficient, robust process with the ability to produce over a thousand doses from one healthy donor. All rights reserved. achapman@atarabio.com, View this news release online at: FUJIFILM Holdings America Corporation Billingham, TS23 1LH January 26, 2022 16:43 ET Powered by Madgex Job Board Software, https://www.businesswire.com/news/home/20220401005459/en/, http://www.businesswire.com/news/home/20220401005459/en. For more information, please visit: https://www.fujifilmholdings.com. FUJIFILM Corporation will continue to expand its bio CDMO business by leveraging its strength of being able to handle a wide variety of biopharmaceutical process development and manufacturing from clinical to commercial scale for drug products, fill & finish, and packaging. The company offers a comprehensive list of services from cell line development using its proprietary pAVEway microbial and ApolloX cell line systems to process development, analytical development, clinical and FDA-approved commercial manufacturing. Beset by challenges, Atara lays off staff and slims R&D focus Atara Biotherapeutics Enters Strategic Manufacturing Partnership with After a series of clinical stumbles, Atara lays off 20% of staff and slims R&D focus. Access. To ensure the most secure and best overall experience on our website, we recommend the latest versions of. Atara will also retain a talented technical operations team to manage external manufacturing, quality, logistics and supply. At closing, Fujifilm plans to offer positions to approximately 140 current highly-skilled manufacturing and quality staff at the site. Excerpt: FUJIFILM Corporation announced that it has completed the acquisition of a dedicated cell therapy manufacturing facility from Atara Biotherapeutics, Inc. for USD 100 million. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. Going forward, Fujifilm will, by providing a stable supply of high quality biopharmaceuticals, further advance establishing tomorrows medicines that fulfill unmet medical needs., We are thrilled that through this acquisition we will add approximately 140 talented staff from Ataras cell therapy manufacturing facility to the FUJIFILM Diosynth Biotechnologies family. Atara expects to report cash, cash equivalents and short-term investments of $371.1 million as of December 31, 2021. We also look forward to adding the facility to FUJIFILM Diosynth Biotechnologies existing global footprint and to bolster the expansion of our advanced therapies CDMO business., FUJIFILM Diosynth Biotechnologies is a highly respected industry-leading manufacturing and development organization that shares our pioneering culture and belief that allogeneic cell therapies will transform the future of medicine, said Pascal Touchon, president and chief executive officer, Atara. ATOM is a 90,000 ft cutting edge T-cell therapy manufacturing facility fully qualified to support clinical and commercial production and designed with the flexibility to expand to support various production requirements and capacities. ft. site is readily expandable to add capacity and has the flexibility to produce both clinical and commercial cell therapies including allogeneic T-cell and CAR T immunotherapies. Mitsubishi Corporation is a 20% shareholder of FUJIFILM Diosynth Biotechnologies UK, Research Triangle Park, North Carolina, Watertown, Massachusetts and College Station, Texas sites. 2023 Atara Biotherapeutics, Inc. All rights reserved. Following completion of the transaction, FDB, a leading contract development and manufacturing organization (CDMO) in advanced therapies, will provide Atara with access to the flexible capacity and specific capability needed to manufacture clinical and commercial-stage allogeneic cell therapies for its maturing and promising pipeline, including tabelecleucel (tab-cel), under regulatory review in Europe for EBV+ PTLD, ATA188 for multiple sclerosis, and allogeneic CAR T therapies, ATA3271 and ATA3219. In its pursuit to establish itself as a comprehensive healthcare company covering prevention, treatment and diagnosis, FUJIFILM Corporation has made multiple strategic acquisitions over recent years to expand and diversify its healthcare portfolio. Article Summary FUJIFILM has acquired the facility from Atara Biotherapeutics which is located in Thousand Oaks, California. To be the leading and most trusted global Contract Development and Manufacturing Organization in the biopharmaceutical industry. With our lead program in Phase 3 clinical development and currently under review to support registration in Europe, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. April 28, 2023. The parties will also enter a long-term supply agreement, which could extend to ten years. To improve your experience, we use cookies to remember log-in details and provide secure log-in, collect statistics to optimize site functionality and deliver content tailored to your interest.By continuing to use this site you are giving us your consent to do this. Fujifilm Completes Acquisition of a Dedicated Cell Therapy 805-395-9669 We are thrilled that through this acquisition we will add approximately 140 talented staff from Ataras cell therapy manufacturing facility to the FUJIFILM Diosynth Biotechnologies family. 04:05PM. FUJIFILM Corporation is an operating company of FUJIFILM Holdings Corporation. These forward-looking statements are subject to risks and uncertainties, including, without limitation, risks and uncertainties associated with the costly and time-consuming pharmaceutical product development process and the uncertainty of clinical success; the COVID-19 pandemic, which may significantly impact (i) our business, research, clinical development plans and operations, including our operations in South San Francisco and Southern California and at our clinical trial sites, as well as the business or operations of our third-party manufacturer, contract research organizations or other third parties with whom we conduct business, (ii) our ability to access capital, and (iii) the value of our common stock; the sufficiency of Ataras cash resources and need for additional capital; and other risks and uncertainties affecting Ataras and its development programs, including those discussed in Ataras filings with the Securities and Exchange Commission (SEC), including in the Risk Factors and Managements Discussion and Analysis of Financial Condition and Results of Operations sections of the Companys most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings and in the documents incorporated by reference therein. Investors This information is preliminary, has not been audited, and is subject to change upon the audit of the companys financial statements for the year ended December 31, 2021. Atara Biotherapeutics Announces the Completion of the Acquisition of Our team has developed processes for our products, scaled them up, and built inventory for clinical trials and the commercial launch of tab-cel. The upfront consideration, along with the reduction in operating expenses, in addition to Ataras existing cash, cash equivalents and short-term investments is expected to fund Ataras planned operations into Q4 2023, beyond the anticipated completion of the randomized, placebo-controlled Phase 2 study of ATA188, the Companys investigational off-the-shelf T-cell candidate that has the potential to reverse disability in progressive multiple sclerosis. The Engineering MSAT team supports the technical activities associated with T-cell manufacturing across the Atara manufacturing network. SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that it has entered into a long term strategic agreement with FUJIFILM Diosynth Biotechnologies (FDB), a subsidiary of FUJIFILM Corporation (Fujifilm) under which Fujifilm will acquire Ataras T-Cell Operations and Manufacturing (ATOM) facility in Thousand Oaks, California for USD 100 million upfront, retaining current manufacturing and quality staff at the site. Sie knnen Ihre Einstellungen jederzeit ndern, indem Sie auf unseren Websites und Apps auf den Link Datenschutz-Dashboard klicken. Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that it has entered into a long term strategic agreement with FUJIFILM Diosynth Biotechnologies (FDB), a subsidiary of FUJIFILM Corporation (Fujifilm) under which Fujifilm will acquire Ataras T-Cell Operations and Manufacturing (ATOM) facility in Thousand Oaks, California for USD 100 million upfront, retaining current manufacturing and quality staff at the site. This partnership and acquisition was first announced in January 2022. The company's lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of . Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel in Phase 3 development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies. Improving patients lives is our mission and we will never stop working to bring transformative therapies to those in need. The 90,000 sq. Evercore Group LLC is acting as strategic advisor to Atara and Gibson Dunn & Crutcher LLP is acting as its legal counsel. Atara Biotherapeutics Announces $31 Million Royalty Interest Financing The collective expertise of the team will further support our efforts as a world-class CDMO, added Martin Meeson, chief executive officer, FUJIFILM Diosynth Biotechnologies. +1 979 431 3500, Biotek All 1 Its proprietary core technologies contribute to the various fields including healthcare, highly functional materials, document solutions and imaging products. 2023 Atara Biotherapeutics, Inc. All rights For the year ended March 31, 2021, the company had global revenues of $21 billion, at an exchange rate of 106 yen to the dollar. Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. Studies, Expanded December 20, 2022 Atara Biotherapeutics Announces $31 Million Royalty Interest Financing Agreement with HealthCare Royalty READ MORE December 19, 2022 Atara Biotherapeutics' Ebvallo (tabelecleucel) Receives European Commission Approval as First Ever Therapy for Adults and Children with EBV+ PTLD READ MORE MORE NEWS Dig deeper. It will be operated as part of FUJIFILM Diosynth Biotechnologies' global network . ATRA - Atara Biotherapeutics, Inc. Stock Price and Quote - FINVIZ.com FUJIFILM Corporation is an operating company of FUJIFILM Holdings Corporation. Our team has developed processes for our products, scaled them up, and built inventory for clinical trials and the commercial launch of tab-cel. 805-395-9669 An archived replay will be available on the Company's website for 30 days. in fighting diseaseto develop transformative therapies for patients with cancer and autoimmune conditions. Atara Biotherapeutics, Inc. (Nasdaq: ATRA), today announced that it has entered into a long term strategic agreement with FUJIFILM Diosynth Biotechnologies (FDB). We are thrilled that through this acquisition we will add approximately 140 talented staff from Ataras cell therapy manufacturing facility to the FUJIFILM Diosynth Biotechnologies family. Improving patients lives is our mission and we will never stop working to bring transformative therapies to those in need. Its proprietary core technologies contribute to the various fields including healthcare, highly functional materials, document solutions and imaging products. FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation, is a world-leading contract development and manufacturing organization (CDMO) with experience in the development and manufacture of biologics, vaccines and advanced therapies. +1 617 798 5211. FDB will also expand use of the Thousand Oaks site and leverage its talented staff to manufacture a broader portfolio of cell therapies. View source version on businesswire.com: https://www.businesswire.com/news/home/20220126006000/en/, INVESTORS & MEDIA: We also look forward to adding the facility to FUJIFILM Diosynth Biotechnologies existing global footprint and to bolster the expansion of our advanced therapies CDMO business.. FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation, is a world-leading contract development and manufacturing organization (CDMO) with experience in the development and manufacture of biologics, vaccines and advanced therapies. Fujifilm Expands its Advanced Therapies CDMO Business with the These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. Because such statements deal with future events and are based on Ataras current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Atara could differ materially from those described in or implied by the statements in this press release. Sclerosis, Clinical The parties will also enter a long-term supply agreement, which could extend to ten years. 2023 Atara Biotherapeutics, Inc. All rights Atara retains the recently established Thousand Oaks-based Atara Research Center (ARC), which is fully operational and will house Ataras Pre-Clinical, Translational Sciences, Manufacturing Process Sciences, and Analytical Development teams to further drive innovation by leveraging the Companys unique and differentiated allogeneic cell therapy platform. Atara is an allogeneic T-cell immunotherapy company. These forward-looking statements are subject to risks and uncertainties, including, without limitation, risks and uncertainties associated with the costly and time-consuming pharmaceutical product development process and the uncertainty of clinical success; the COVID-19 pandemic, which may significantly impact (i) our business, research, clinical development plans and operations, including our operations in South San Francisco and Southern California and at our clinical trial sites, as well as the business or operations of our third-party manufacturer, contract research organizations or other third parties with whom we conduct business, (ii) our ability to access capital, and (iii) the value of our common stock; the sufficiency of Ataras cash resources and need for additional capital; and other risks and uncertainties affecting Ataras and its development programs, including those discussed in Ataras filings with the Securities and Exchange Commission (SEC), including in the Risk Factors and Managements Discussion and Analysis of Financial Condition and Results of Operations sections of the Companys most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings and in the documents incorporated by reference therein. Located in Thousand Oaks, California, the facility is readily expandable with the flexibility to produce both clinical and commercial cell therapies including allogeneic T-cell and CAR T immunotherapies. Fujifilm Completes Acquisition of a Dedicated Cell Therapy Manufacturing Facility from Atara Biotherapeutics, Inc. Press release 2023-04-19, Press release 2022-11-15, Press release 2022-10-27, In Person Lunch & Learn | Process Characterization, Paveway PLUS Microbial Expression Platform, FUJIFILM Diosynth Biotechnologies and RoosterBio Announce Collaboration to enable GMP Manufacturing of Cell and Exosome Therapies. Located in Thousand Oaks, California, the facility is readily expandable with the flexibility to produce both clinical and commercial cell . These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. Because such statements deal with future events and are based on Ataras current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Atara could differ materially from those described in or implied by the statements in this press release.
Call Center Supervisor Daily Checklist, David Hawkins Illness, Articles A
atara biotherapeutics acquisition 2023